Vadadustat Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 150 mg, 300 mg
Reference Brands: Vafseo (EU/EU/UK)
Category:
Anemia
Vadadustat is available in Tablets
and strengths such as 150 mg, 300 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Vadadustat is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Vadadustat can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Vadadustat is an oral medication used for the treatment of symptomatic anemia associated with chronic kidney disease (CKD), particularly in adult patients who are on dialysis. Anemia is a common complication in CKD due to reduced production of erythropoietin, a hormone responsible for stimulating red blood cell formation. Vadadustat works by inhibiting hypoxia-inducible factor prolyl hydroxylase (HIF-PH) enzymes, which helps stabilize hypoxia-inducible factors in the body. This process stimulates the natural production of erythropoietin, improves iron metabolism, and supports the formation of red blood cells.
By targeting the body’s natural response to low oxygen levels, vadadustat offers a different mechanism compared to traditional erythropoiesis-stimulating agents (ESAs). The medicine is administered orally in tablet form, making it a convenient treatment option for patients requiring long-term anemia management due to kidney disease. Vadadustat is marketed under the brand name Vafseo in several regulated pharmaceutical markets. It has been developed to help maintain hemoglobin levels within a target range and reduce the need for blood transfusions in eligible patients. The drug is typically prescribed and monitored by healthcare professionals experienced in managing anemia in chronic kidney disease patients.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing